Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer J-P, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM (2018) CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin’s lymphoma. N Engl J Med 379:1711–1721. https://doi.org/10.1056/nejmoa1807315

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ait-Oufella H, Salomon BL, Potteaux S, Robertson AKL, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12:178–180. https://doi.org/10.1038/nm1343

Article  CAS  PubMed  Google Scholar 

Alhumaid W, Yogasundaram H, Senaratne JM (2021) Slow bidirectional ventricular tachycardia as a manifestation of immune checkpoint inhibitor myocarditis. Eur Heart J 42:2868. https://doi.org/10.1093/eurheartj/ehab219

Article  PubMed  Google Scholar 

Ali A, Caldwell R, Pina G, Beinart N, Jensen G, Yusuf SW, Koutroumpakis E, Hamzeh I, Khalaf S, Iliescu C, Deswal A, Palaskas NL (2024) Elevated IL-6 and tumor necrosis factor-α in immune checkpoint inhibitor myocarditis. Diseases 12:1–11. https://doi.org/10.3390/diseases12050088

Article  CAS  Google Scholar 

Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B, Spano JP, Ederhy S, Klatzmann D, Rosenzwajg M, Fautrel B, Cadranel J, Johnson DB, Moslehi JJ, Salem JE (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19:102586. https://doi.org/10.1016/j.autrev.2020.102586

Article  CAS  PubMed  Google Scholar 

Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL (2019) Immune checkpoint inhibitor-associated pericarditis. J Thorac Oncol 14:1102–1108. https://doi.org/10.1016/j.jtho.2019.02.026

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amiri-Kordestani L, Moslehi J, Cheng J, Tang S, Schroeder R, Sridhara R, Karg K, Connolly J, Beaver JA, Blumenthal GM, Pazdur R (2018) Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: a U.S. Food and drug administration pooled analysis. J Clin Oncol 36:3009. https://doi.org/10.1200/JCO.2018.36.15_suppl.3009

Article  Google Scholar 

Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, Hanna A, Zhang S, Amancherla K, Tai W, Wright JJ, Wei SC, Opalenik SR, Toren AL, Rathmell JC, Ferrell PB, Phillips EJ, Mallal S, Johnson DB, Allison JP, Moslehi JJ, Balko JM (2022) T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature. https://doi.org/10.1038/s41586-022-05432-3

Article  PubMed  PubMed Central  Google Scholar 

Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS, Fonarow GC, Lenihan DJ, Bhatt DL (2019) Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week. j am coll cardiol 74:1714–1727. https://doi.org/10.1016/j.jacc.2019.07.079

Article  CAS  PubMed  Google Scholar 

Barrett TJ (2020) Macrophages in atherosclerosis regression. Arterioscler Thromb Vasc Biol 40:20–33. https://doi.org/10.1161/ATVBAHA.119.312802

Article  CAS  PubMed  Google Scholar 

Boesten LSM, Zadelaar ASM, Van Nieuwkoop A, Gijbels MJJ, De Winther MPJ, Havekes LM, Van Vlijmen BJM (2005) Tumor necrosis factor-α promotes atherosclerotic lesion progression in APOE*3-leiden transgenic mice. Cardiovasc Res 66:179–185. https://doi.org/10.1016/j.cardiores.2005.01.001

Article  CAS  PubMed  Google Scholar 

Boland P, Heath J, Sandigursky S (2020) Immune checkpoint inhibitors and vasculitis. Curr Opin Rheumatol 32:53–56. https://doi.org/10.1097/BOR.0000000000000672

Article  CAS  PubMed  Google Scholar 

Bu DX, Tarrio M, Maganto-Garcia E, Stavrakis G, Tajima G, Lederer J, Jarolim P, Freeman GJ, Sharpe AH, Lichtman AH (2011) Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol 31:1100–1107. https://doi.org/10.1161/ATVBAHA.111.224709

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bukamur HS, Mezughi H, Karem E, Shahoub I, Shweihat Y (2019) Nivolumab-induced third degree atrioventricular block in a patient with stage IV squamous cell lung carcinoma. Cureus 11:10–13. https://doi.org/10.7759/cureus.4869

Article  Google Scholar 

Cadena RH, Abdulahad WH, Hospers GAP, Wind TT, Boots AMH, Heeringa P, Brouwer E (2018) Checks and balances in autoimmune vasculitis. Front Immunol 9:1–11. https://doi.org/10.3389/fimmu.2018.00315

Article  CAS  Google Scholar 

Calabretta R, Hoeller C, Pichler V, Mitterhauser M, Karanikas G, Haug A, Li X, Hacker M (2020) Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries. Circulation 142:2396–2398. https://doi.org/10.1161/CIRCULATIONAHA.120.048708

Article  CAS  PubMed  Google Scholar 

Champion SN, Stone JR (2020) Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Mod Pathol 33:99–108. https://doi.org/10.1038/s41379-019-0363-0

Article  CAS  PubMed  Google Scholar 

Chen YH, Kovács T, Ferdinandy P, Varga ZV (2024) Treatment options for immune-related adverse events associated with immune checkpoint inhibitors. Br J Pharmacol. https://doi.org/10.1111/bph.16405

Article  PubMed  Google Scholar 

Cheniti G, Vlachos K, Pambrun T, Hooks D, Frontera A, Takigawa M, Bourier F, Kitamura T, Lam A, Martin C, Dumas-Pommier C, Puyo S, Pillois X, Duchateau J, Klotz N, Denis A, Derval N, Jais P, Cochet H, Hocini M, Haissaguerre M, Sacher F (2018) Atrial fibrillation mechanisms and implications for catheter ablation. Front Physiol 9:1–24. https://doi.org/10.3389/fphys.2018.01458

Article  Google Scholar 

Cochain C, Chaudhari SM, Koch M, Wiendl H, Eckstein H-H, Zernecke A (2014) Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. PLoS ONE 9:e93280

Article  PubMed  PubMed Central  Google Scholar 

Cochain C, Vafadarnejad E, Arampatzi P, Pelisek J, Winkels H, Ley K, Wolf D, Saliba AE, Zernecke A (2018) Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. Circ Res 122:1661–1674. https://doi.org/10.1161/CIRCRESAHA.117.312509

Article  CAS  PubMed  Google Scholar 

Cole JE, Park I, Ahern DJ, Kassiteridi C, Abeam DD, Goddard ME, Green P, Maffia P, Monaco C (2018) Immune cell census in murine atherosclerosis: cytometry by time of flight illuminates vascular myeloid cell diversity. Cardiovasc Res 114:1360–1371. https://doi.org/10.1093/cvr/cvy109

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cuddy S, Payne DL, Murphy DJ, Dunne RM, Bueno R, Blankstein R, Di Carli M, Mehra MR, Nohria A, Groarke JD (2019) Incidental coronary artery calcification in cancer imaging. JACC CardioOncol 1:135–137. https://doi.org/10.1016/j.jaccao.2019.08.005

Article  PubMed  PubMed Central  Google Scholar 

Dietel B, Cicha I, Voskens CJ, Verhoeven E, Achenbach S, Garlichs CD (2013) Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells. Atherosclerosis 230:92–99. https://doi.org/10.1016/j.atherosclerosis.2013.06.014

Article  CAS  PubMed  Google Scholar 

Dolladille C, Akroun J, Morice PM, Dompmartin A, Ezine E, Sassier M, Da-Silva A, Plane AF, Legallois D, L’Orphelin JM, Alexandre J (2021) Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J 42:4964–4977. https://doi.org/10.1093/eurheartj/ehab618

Article  CAS  PubMed  Google Scholar 

Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, Sassier M, Plane AF, Comoz F, Cohen AA, Thuny FR, Cautela J, Alexandre J (2020) Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer 8:1–10. https://doi.org/10.1136/jitc-2019-000261

Article  Google Scholar 

Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, Hartmann SE, Gilman HK, Gong J, Zubiri L, Sullivan RJ, Reynolds KL, Mayrhofer T, Zhang L, Hoffmann U, Neilan TG (2020) Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.120.049981